Cipla Shares Slip Despite USFDA Nod for Generic Ventolin Inhaler; Should You Buy or Sell This Pharma Stock?

Cipla Limited’s shares edge lower despite a key United States regulatory approval, keeping pressure on the pharmaceutical company’s market performance. The stock slips 1.27 per cent to ₹1,289.30 on the NSE even as investors weigh prospects from the newly cleared generic asthma inhaler and Cipla’s recent track record on the index.

Cipla Shares Slip Despite US Approval; Stock Under Pressure

At the opening bell, Cipla trades at ₹1,295, matching the intraday high before easing. The day’s low hits ₹1,254.10. Turnover crosses ₹217 crore, with about 17.06 lakh shares changing hands. Buy orders form 54 per cent of traded quantity, while sell orders account for 46 per cent, showing mixed sentiment around the counter.

Cipla Share Price Today Vs Nifty 50 Today

Cipla continues to lag the wider market. The stock is down 14.36 per cent in 2026 so far and has fallen 17.17 per cent over the past year. In the same period, the Nifty 50 index has slipped only 1.21 per cent. Cipla’s 52-week high of ₹1,673 came in October 2025, while the 52-week low of ₹1,165.70 was touched on April 2.

Cipla Secures USFDA Nod for Generic Ventolin Inhaler; Targets $1.5 Billion US Asthma Market

Market focus turns to Cipla USA Inc., which receives final USFDA approval for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation. The product is the first AB-rated generic version of GlaxoSmithKline’s Ventolin HFA. Cipla plans to launch the inhaler in the first half of FY2026-27, targeting a United States albuterol market worth about $1.5 billion. The approved inhaler will be produced at Cipla’s dedicated inhalation facility in Fall River, Massachusetts.

Should You Buy, Hold or Sell Cipla Stock? Check Morgan Stanley's Recommendation

Morgan Stanley keeps an Underweight view on Cipla but raises the target price slightly to ₹1,237 from ₹1,211. The brokerage values the Ventolin HFA generic at $130 million in FY27 sales, expecting around a 4 per cent lift to earnings per share.

According to Morgan Stanley, gains from the Albuterol launch could partly balance pressure on Lanreotide sales and support Cipla’s respiratory portfolio. However, the firm warns that Cipla’s outlook still depends heavily on executing its product pipeline, which remains a key risk for investors tracking the counter.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.